{"id":"W4391288586","doi":"10.1016/j.ejca.2024.113580","title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Aptitude Health; AbbVie","keywords":"Veliparib; Carboplatin; Paclitaxel; Medicine; Oncology; Internal medicine; Breast cancer; Chemotherapy; Cancer; Biology; Cisplatin; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00188082,0.001358475,0.002139138,0.000334541,0.0004054354,0.001471075,0.000967672,0.00127095,0.004757834],"category_scores_gemma":[0.001125199,0.0005103501,0.002426688,0.0005167747,0.0009886614,0.0010429,0.0004957866,0.003625067,0.0008114692],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001261736,"about_ca_system_score_gemma":0.00119635,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001540971,"about_ca_topic_score_gemma":0.004351085,"domain_scores_codex":[0.9994515,0.000262252,0.0000256984,0.0001038936,0.00004104823,0.0001155433],"domain_scores_gemma":[0.9994073,0.0001515066,0.0001407252,0.00005764564,0.00002630506,0.0002165065],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9464719,0.005537436,0.001279481,0.0005894351,0.002350227,0.0000674443,0.00007478772,0.001559883,0.004387693,0.0002319593,0.002520802,0.03492892],"study_design_scores_gemma":[0.9544431,0.03873491,0.003078404,0.00004169593,0.001005587,0.00007728555,0.0000309298,0.0005372129,0.0005061209,0.0002662105,0.001257294,0.00002137712],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845585,0.006486569,0.0006521951,0.001102769,0.0002746746,0.001880226,0.002194849,0.000165377,0.002684975],"genre_scores_gemma":[0.9828644,0.004665502,0.001433896,0.001624315,0.000211524,0.002232524,0.003694588,0.00007337622,0.003199883],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004757834,"threshold_uncertainty_score":0.01591653,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03210246603371406,"score_gpt":0.346698349754391,"score_spread":0.3145958837206769,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}